» Articles » PMID: 31307551

Prediction for Early Recurrence of Intrahepatic Mass-forming Cholangiocarcinoma: Quantitative Magnetic Resonance Imaging Combined with Prognostic Immunohistochemical Markers

Overview
Journal Cancer Imaging
Publisher Springer Nature
Specialties Oncology
Radiology
Date 2019 Jul 17
PMID 31307551
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Partial hepatectomy is the first option for intrahepatic mass-forming cholangiocarcinoma (IMCC) treatment, which would prolong survival. The main reason for the poor outcome after curative resection is the high incidence of early recurrence (ER). The aim of this study was to investigate the combined predictive performance of qualitative and quantitative magnetic resonance imaging (MRI) features and prognostic immunohistochemical markers for the ER of IMCC.

Methods: Forty-seven patients with pathologically proven IMCC were enrolled in this retrospective study. Preoperative contrast-enhanced MRI and post-operative immunohistochemical staining of epidermal growth factor receptors (EGFR), vascular endothelial growth factor receptor (VEGFR), P53 and Ki67 were performed. Univariate analysis identified clinic-radiologic and pathological risk factors of ER. Radiomics analysis was performed based on four MRI sequences including fat suppression T2-weighted imaging (T2WI/FS), arterial phase (AP), portal venous phase (PVP), and delayed phase (DP) contrast enhanced imaging. A clinicoradiologic-pathological (CRP) model, radiomics model, and combined model were developed. And ROC curves were used to explore their predictive performance for ER stratification.

Results: Enhancement patterns and VEGFR showed significant differences between the ER group and non-ER group (P = 0.001 and 0.034, respectively). The radiomics model based on AP, PVP and DP images presented superior AUC (0.889, 95% confidence interval (CI): 0.783-0.996) among seven radiomics models with a sensitivity of 0.938 and specificity of 0.839. The combined model, containing enhancement patterns, VEGFR and radiomics features, showed a preferable ER predictive performance compared to the radiomics model or CRP model alone, with AUC, sensitivity and specificity of 0.949, 0.875 and 0.774, respectively.

Conclusions: The combined model was the superior predictive model of ER. Combining qualitative and quantitative MRI features and VEGFR enables ER prediction, thus facilitating personalized treatment for patients with IMCC.

Citing Articles

Exploring a multiparameter MRI-based radiomics approach to predict tumor proliferation status of serous ovarian carcinoma.

Liu L, Zhao L, Jing Y, Li D, Linghu H, Wang H Insights Imaging. 2024; 15(1):74.

PMID: 38499907 PMC: 10948697. DOI: 10.1186/s13244-024-01634-7.


Identifying patients suitable for targeted adjuvant therapy: advances in the field of developing biomarkers for tumor recurrence following irradiation.

Jagasia S, Tasci E, Zhuge Y, Camphausen K, Krauze A Expert Rev Precis Med Drug Dev. 2023; 8(1):33-42.

PMID: 37982134 PMC: 10655913. DOI: 10.1080/23808993.2023.2276927.


Preoperative MRI features predicting very early recurrence of intrahepatic mass-forming cholangiocarcinoma after R0 resection: a comparison with the AJCC 8th edition staging system.

Chen S, Wan L, Zhao R, Peng W, Zou S, Zhang H Abdom Radiol (NY). 2023; 49(1):21-33.

PMID: 37815613 DOI: 10.1007/s00261-023-04038-1.


Postoperative Prognosis of Non-alcoholic Fatty Liver Disease-Associated Intrahepatic Cholangiocarcinoma: a Multi-center Propensity Score Matching Analysis.

Yu Q, Lei Z, Ma W, Yang F, Tang H, Xiao Q J Gastrointest Surg. 2023; 27(11):2403-2413.

PMID: 37582919 DOI: 10.1007/s11605-023-05794-7.


Update on the Applications of Radiomics in Diagnosis, Staging, and Recurrence of Intrahepatic Cholangiocarcinoma.

Brunese M, Fantozzi M, Fusco R, De Muzio F, Gabelloni M, Danti G Diagnostics (Basel). 2023; 13(8).

PMID: 37189589 PMC: 10137417. DOI: 10.3390/diagnostics13081488.


References
1.
Asayama Y, Yoshimitsu K, Irie H, Tajima T, Nishie A, Hirakawa M . Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma. Radiology. 2005; 238(1):150-5. DOI: 10.1148/radiol.2381041765. View

2.
Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S . Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2007; 98(2):418-25. PMC: 2361442. DOI: 10.1038/sj.bjc.6604129. View

3.
Iguchi T, Yamashita N, Aishima S, Kuroda Y, Terashi T, Sugimachi K . A comprehensive analysis of immunohistochemical studies in intrahepatic cholangiocarcinoma using the survival tree model. Oncology. 2009; 76(4):293-300. DOI: 10.1159/000207506. View

4.
Chung Y, Kim M, Park Y, Choi J, Pyo J, Kim Y . Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics. 2009; 29(3):683-700. DOI: 10.1148/rg.293085729. View

5.
Jiang W, Zeng Z, Tang Z, Fan J, Sun H, Zhou J . A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score. Ann Oncol. 2011; 22(7):1644-1652. DOI: 10.1093/annonc/mdq650. View